Patents by Inventor Lee M. Kaplan

Lee M. Kaplan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236392
    Abstract: Methods and compositions are generally provided for treating metabolic disorders, e.g., obesity. One aspect discloses methods and compositions for obtaining a biological sample from the subject, evaluating the sample for the presence or absence of a genetic indicator, wherein the genetic indicator is selected from a single nucleotide polymorphism and a level of gene expression, and performing a first metabolic procedure if the genetic indicator is present, or performing an alternative second metabolic procedure if the genetic indicator is absent. One aspect discloses methods and compositions for obtaining a sample including deoxyribonucleic acids (DNA) from the subject, evaluating the DNA for an absence or presence of one or more genetic indicators and performing a first metabolic procedure or an alternative second metabolic procedure based on the absence or presence of the genetic indicator(s). Other aspects are also disclosed.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: February 1, 2022
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation General Hospital
    Inventors: Lee M. Kaplan, Ida Hatoum, Jason L. Harris
  • Patent number: 11154559
    Abstract: Methods and compositions are provided for treating metabolic disorders by modulating bile acid levels. Generally, the methods and compositions can modulate bile acid levels, such as serum bile acid levels, to treat a metabolic disorder. In one embodiment, a method of modulating a bile acid level includes measuring a bile acid level and delivering a composition effective to modulate the bile acid level. A method for modulating a bile acid profile includes comparing a bile acid profile to a target profile and delivering a bile acid cocktail to increase bile acid levels. In another embodiment, a pharmaceutical composition for increasing bile acid levels includes a bile acid cocktail effective to increase bile acid levels. The composition is further useful as part of an implantable system.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: October 26, 2021
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Lee M. Kaplan, Nadia N. Ahmad, Jason L. Harris, Kevin D. Felder, Alessandro Pastorelli
  • Patent number: 11040196
    Abstract: Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and/or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 22, 2021
    Assignees: Cilag GmbH International, The General Hospital Corporation
    Inventors: Jason L. Harris, Nicholas Stylopoulos, Lee M. Kaplan, Tamara C. Baynham, Taylor W. Aronhalt
  • Publication number: 20200246395
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: March 26, 2020
    Publication date: August 6, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10729732
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: August 4, 2020
    Assignees: Ethicon Endo Surgery, Inc., The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Publication number: 20200237835
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: March 26, 2020
    Publication date: July 30, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10668104
    Abstract: Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: June 2, 2020
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Lee M. Kaplan, Nicholas Stylopoulos, Jason L. Harris, Dwight Henninger, Taylor W. Aronhalt, James W. Voegele
  • Publication number: 20200121734
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Publication number: 20200121736
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Publication number: 20200121733
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Publication number: 20200121735
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 23, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Publication number: 20200121732
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 23, 2020
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10441808
    Abstract: Methods and devices are provided for activating brown adipose tissue (BAT) with light. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a medical device is provided that activates BAT by using light to stimulate nerves that activate the BAT and/or to stimulate brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure. The light can be configured to directly or indirectly stimulate the nerves and/or the brown adipocytes. The light can be configured to indirectly stimulate the nerves and/or the brown adipocytes by activating a light activatable medium administered to a patient and configured to respond to the light to cause activation of the brown adipose tissue.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 15, 2019
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Jason L. Harris, Lee M. Kaplan, David N. Plescia, Taylor W. Aronhalt, James W. Voegele, Nicholas Stylopoulos
  • Patent number: 10441459
    Abstract: Methods and devices are provided for activating brown adipose tissue (BAT) with cooling. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a medical device is provided that activates BAT by cooling tissue having a high density of cold sensitive thermoreceptors and/or by cooling BAT depots directly, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 15, 2019
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Taylor W. Aronhalt, Lee M. Kaplan, Nicholas Stylopoulos, Jason L. Harris, Dwight Henninger, James W. Voegele, Mark S. Ortiz
  • Publication number: 20190083774
    Abstract: Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and/or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Inventors: Jason L. Harris, Nicholas Stylopoulos, Lee M. Kaplan, Tamara C. Baynham, Taylor W. Aronhalt
  • Publication number: 20190046590
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Application
    Filed: October 12, 2018
    Publication date: February 14, 2019
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10201695
    Abstract: Methods and devices are provided for activating brown adipose tissue (BAT). Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss. In one embodiment, a medical device is provided that activates BAT by electrically stimulating nerves that activate the BAT and/or electrically stimulating brown adipocytes directly, thereby increasing thermogenesis in the BAT and inducing weight loss through energy expenditure.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 12, 2019
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Jason L. Harris, Nicholas Stylopoulos, Lee M. Kaplan, Tamara C. Baynham, Taylor W. Aronhalt
  • Patent number: 10149870
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: December 11, 2018
    Assignees: The General Hospital Corporation, Ethicon Endo-Surgery, Inc., President and Fellows of Harvard College
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10149867
    Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: December 11, 2018
    Assignees: The General Hospital Corporation, Ethicon Endo-Surgery, Inc., President and Fellows of Harvard College
    Inventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
  • Patent number: 10111770
    Abstract: Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and/or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and/or systemically to stimulate the nerves and/or the brown adipocytes.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 30, 2018
    Assignees: Ethicon Endo-Surgery, Inc., The General Hospital Corporation
    Inventors: Jason L. Harris, Taylor W. Aronhalt, Dwight Henninger, James W. Voegele, Lee M. Kaplan, Nicholas Stylopoulos